SCHEMBL7143478

SCHEMBL7143478

Fc1ccc(-c2ncc(-c3cccc(CNC4CCC4)c3)[nH]2)cc1

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.49
CNR2 P34972 9/20 0.45
CNR1 P21554 3/20 0.45
BACE1 P56817 1/20 0.43
MAP4K4 O95819 2/20 0.43
HPGDS O60760 2/20 0.43
VCP P55072 1/20 0.42
PARP1 P09874 1/20 0.42
SCN2A Q99250 2/20 0.41
CYP2D6 P10635 1/20 0.41
GRIN2B Q13224 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8190593 0.99 KCNH2 (0.48) KCNH2CNR2CNR1BACE1MAP4K4
SCHEMBL8119014 0.97 KCNH2 (0.51) KCNH2CNR2CNR1BACE1MAP4K4
SCHEMBL7138368 0.96 CNR2 (0.47) KCNH2CNR2CNR1BACE1MAP4K4
SCHEMBL8118669 0.92 KCNH2 (0.46) KCNH2CNR2CNR1BACE1MAP4K4
SCHEMBL8117997 0.91 SCN2A (0.50) CNR2CNR1MAP4K4HPGDSVCP
SCHEMBL7139526 0.89 SCN2A (0.50) KCNH2CNR2CNR1MAP4K4HPGDS
SCHEMBL7142302 0.86 SCN2A (0.52) CNR2CNR1MAP4K4HPGDSVCP
SCHEMBL7143623 0.81 BACE1 (0.46) CNR2CNR1BACE1MAP4K4HPGDS
SCHEMBL8190596 0.80 CNR2 (0.46) CNR2CNR1BACE1HPGDSSCN2A
SCHEMBL7142281 0.80 SCN2A (0.47) CNR2CNR1BACE1HPGDSSCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed